DSRV Articles
Warning-letter analysis, 483 trend reports, and regulatory intelligence for pharma quality teams. Every piece is cited, verified, and written by our Intelligence team.
14 of 48 articles · Regulatory Update·Browse by regulation →
July 2026
MCP Goes Stateless on July 28. For Pharma AI Teams, That Is a Change Control Event.
The MCP protocol's July 28 release candidate introduces six breaking changes and deprecates three core primitives. For pharma teams running MCP-enabled tools, the deadline is a validation checkpoint and a documentation obligation under FDA's AI-CGMP enforcement precedent.
June 2026
What Pharma Quality Teams Need to Know About MCP Governance
Three governance frameworks for MCP-connected AI agents landed in the first week of June 2026. The controls they describe, including audit trails, identity management, sandboxing, and human oversight for high-risk actions, are the same ones 21 CFR Part 11 and EU GMP Annex 11 have required from regulated computer systems for decades. The question is whether your AI agent deployment includes them.
June 2026
FDA Finally Wrote Down What a Good 483 Response Requires
For the first time, FDA has published dedicated draft guidance on what a credible CGMP 483 response must contain. The requirements are not new. The formal standard is.
June 2026
ICH Q8/Q9/Q10 R5 Just Raised the Floor on Risk Documentation
FDA adopted ICH Q8/Q9/Q10 R5 as final Level 2 guidance on May 29, 2026. The alignment with Q9(R1) is the change that matters most for quality systems that still rely on informal risk judgments.
May 2026
What a Recall and a Closeout Letter Say About Quality Systems: Hidden Sildenafil, CAPA Sustainability, and Inspection Readiness
Two FDA actions in May 2026 — a voluntary recall for undeclared sildenafil and a warning-letter closeout with an explicit sustainability caveat — point to the same quality lesson: finding the issue is only the first control.
May 2026
Your 483 Response Has 15 Business Days. FDA Just Defined the Bar.
FDA's March 2026 draft guidance converts the 483 response from a closeout ritual into a formal test of your investigation quality under 21 CFR 211.192.
May 2026
AI Wrote the Documents. FDA's Warning Letter Was Addressed to You.
An April 2026 FDA warning letter cited a drug manufacturer for using AI to generate specifications, procedures, and production records without adequate quality-unit review. The compliance logic has not changed: under GMP, human accountability does not transfer to the tool.
May 2026
EU AI Act Delays High-Risk Deadline to December 2027
EU lawmakers reached a provisional deal on May 7 to push the high-risk AI compliance deadline from August 2, 2026 to December 2, 2027. For pharma quality AI programs, the window is larger. The destination has not moved.
May 2026
FDA's 1-Day Inspection Pilot Changes Inspection Readiness
FDA's 1-day inspection pilot and AI-assisted risk ranking change what inspection readiness means for quality teams: less time to recover, more pressure on records that can stand on their own.
April 2026
FDA Tied Residue, Cleaning Validation, and Component Controls at Chemco
FDA's April 2026 Chemco warning letter links visible residue, missing cleaning validation for shared equipment, and inadequate incoming component identity testing into one quality-system control failure.
March 2026
FDA Just Told You Exactly What It Expects in a 483 Response
FDA's March 2026 draft guidance formalizes for the first time what the agency expects in a 483 response — executive sign-off, risk assessment for distributed product, structured CAPA tables, and a 15-business-day window that is now explicitly tied to enforcement timelines.
March 2026
Your Stability Program Was Built for a Guideline Stack FDA Is Replacing
FDA's June 2025 draft ICH Q1 guidance consolidates the Q1A-F and Q5C stability guideline stack. It is still draft and not for implementation, but it signals where global stability expectations are moving.
March 2026
FDA Data Integrity Enforcement Is Accelerating — Here's What the Warning Letters Actually Say
Data integrity citations appeared in over 60% of pharmaceutical manufacturing warning letters in 2025. FDA is citing the systems that allowed falsification to happen unchallenged — not just the falsification itself. Here is what the enforcement record shows and what separates sites that pass from those that don't.
March 2026
ICH Q14 Analytical Procedure Development: What QA Teams Need to Know
ICH Q14 introduces a structured, science-based approach to analytical procedure development. We break down the key concepts, lifecycle management requirements, and how they align with existing Q2 and Q12 guidelines.
